34 results about "Divided dose" patented technology

The invention discloses a preparation method of pellet-type formula granules. The method comprises the following steps: (1) selecting at least one of the traditional Chinese medicinal materials; (2) respectively extracting the medicinal materials selected in step (1) for obtaining extracts, or respectively grinding the medicinal materials, or respectively carrying out partial extraction and partial grinding, thus obtaining pretreated materials; and (3) preparing the pretreated materials obtained in step (2) into pellets, thus obtaining the pellet-type formula granules. According to the preparation method provided by the invention, on the basis of the prior art, the preparation process of the formula granules is innovated, the formula granules are innovated into pellets, the fluidity and moisture absorption resistance are good, the friability is small, the shape is round and uniform as well as regular, the content uniformity is small, and the divided dose is accurate.

The invention provides an oral ulcer mucoadhesive film and a preparation method thereof. The oral ulcer mucoadhesive film is prepared by honeysuckle flower, menthol, vitamin B [2], borneol, tetracaine hydrochloride, sorbic acid, prednisone acetate, chlortetracycline hydrochloride, glycerin, stevioside, ethanol PVA 17-88 and purified water. Compared with the prior art, the film has good flexibility and tensile strength, can rapidly being expended and dissolved when meets water, a high-density protection drug film layer is formed on the oral cavity mucous membrane, and the effect for rapidly relieving swelling and pain with long term can be reached; oral cavity mucous membrane is employed for direction drug administration, the drug can be directly effected on the disease, simultaneous treatment of principal and subordinate symptoms can be reached, curative effect is fully performed; a lattice impression technology is employed on the technology, administration with divided dose is accurate, curative effect is increased, quality is stable, the oral ulcer mucoadhesive film has no toxic and side effect for oral cavity, and is safe and effective; and has the advantages of small volume, light weight, and convenient carrying and usage.

The invention provides 3D (three dimensional) printed hydrochlorothiazide tablets and a preparation method thereof. The preparation method comprises the following steps: performing accurate divided dose on commercially available hydrochlorothiazide tablets by using a 3D hot melt extrusion technology, firstly, preparing the commercially available hydrochlorothiazide tablets and auxiliary materials into 3D printed hydrochlorothiazide tablet powder, then generating the tablet models with different sizes through the modeling software to determine the dose contained in the tablets, and finally setting the corresponding parameters in a 3D printer to print and prepare the 3D printed hydrochlorothiazide tablets. The 3D printed hydrochlorothiazide tablets prepared by the invention can precisely perform divided dose on the commercially available hydrochlorothiazide tablets to enable the hydrochlorothiazide tablets to be safer in combination with drugs for the treatment of hypertension; aesthetic appearance and integrity are realized, and patient compliance and easier preservation and transportation are improved.

The invention provides an esomeprazole magnesium suspension tablet which is prepared by mixing and tabletting an esomeprazole pill, a filler, corrigent, a disintegrating agent, a suspending agent, a lubricant and the like, wherein the esomeprazole pill is prepared by carrying the medicine in a pill core, wrapping an isolating layer and wrapping an enteric coating. Because of nicking, the esomeprazole magnesium suspension tablet can be torn apart for taking; a small pill tabletting process is adopted, the divided dose is accurate, the enteric effect of the pill is not affected after the tablet is torn apart, the tablet can be reasonably taken according to the age and the weight of children, and the clinical compliance is improved. The esomeprazole magnesium suspension tablet provided by the invention can be rapidly dispersed into suspension, is beneficial for distribution of the medicine in gastrointestinal tracts, can improve the bioavailability of the medicine, and is also applicable to patients with dysphagia.

The invention belongs to the technical field of a medicine slow-release preparation, and particularly relates to slow-release micro-matrix-tablet capsules containing active components namely memantineand a preparation method of the slow-release micro-matrix-tablet capsules. When hydrochloric acid memantine slow-release capsules are taken, the dosage needs to be increased progressively, high dosage requirements are needed, the slow-release micro-matrix-tablet capsules are small in size, each of the slow-release micro-matrix-tablet capsules is about 20-30mg, 4 micro tablets are contained, 4 divided dose units are contained, and the 4 micro tablets can be loaded into small No.4 capsules, so that the slow-release micro-matrix-tablet capsules have great compliance to old people suffering fromAlzheimer's Disease( Alzheimer's Disease, AD). Therefore, if the hydrochloric acid memantine slow-release capsules can be successfully developed, the hydrochloric acid memantine slow-release capsulescan obtain good clinical advantages. Based on the reasons, the recipe of the hydrochloric acid memantine slow-release capsules is firstly researched, but the raw material of hydrochloric acid memantine is good in water solubility, development of matrix slow-release micro tablets is difficult, and the hydrochloric acid memantine is considered to be reduced to memantine (base), and then is preparedinto the memantine slow-release micro-tablet capsules, so that the difficulty of the recipe and technological design can be basically solved, and the memantine slow-release micro-tablet capsules can be successfully developed.

Retinal degenerative diseases affect the delicate layer of retina tissue that lines the inside back of the eye leading to gradual vision loss. The use of opioid anatgonists for the preparation of a medicament for the selective blocking of the body's opioid receptors sites is a method of treating this human suffering by daily administration to the patient of from about 0.5 to about 10 mg of drugs such as naltrexone, naloxone or nalmefene. They act primarily by normalizing derangements in the human complement system that may occur in the disease etiology. Therapeutical approach for macular degeneration and retinitis pigmentosa is primarily intended. Oral, parenteral uses as well as topical applications may all be considered. They may be administered in one or divided doses daily for the best receptor blocking activity, preferably in the evening hours. Low Dose Naltrexone suitable for oral administration is most preferred regimen at about 4.5 mg/day.

Therapeutic regimes for improving visual function in a subject having a deficiency in endogenously produced 11-cis retinal comprising administering the synthetic retinal derivative as a divided dose over 2-7 days then providing a resting period of 7-28 days after which the second dose of the synthetic retinal derivative is administered. Preferred synthetic retinal derivatives are 9-or 11-cis-retinyl esters. Disorders associated with deficiency in endogenously produced 11-cis retinal include retinitis pigmentosa and Leber congenital amaurosis

The invention discloses a method for preparing a medicament for treating cyclomastopathy. The technical scheme comprises the following steps of: soaking pinellia tuber with ginger juice for 1 hour and mixing at the same time; baking the mixture over a tile; soaking common bletilla pseudobulb with artemisia argyi-vinegar soup for 1 hour, and airing; adding water into common bletilla pseudobulb, dandelion, rhizoma anemarrhenae, Chinese honeylocust spine and frankincense, decocting for 15 minutes and filtering to obtain decoction; adding water, decocting for 20 minutes and removing the residues; and uniformly mixing the decoction obtained twice and taking in divided doses. The method can obviously improve the curative effect.

The invention discloses a compound oral solution for treating infantile cough, which is prepared from the following raw materials in parts by weight through active ingredient extraction, purification and formation: 21 parts of ginseng, 19.5 parts of tuckahoe, 9 parts of bighead atractylodes rhizome, 18.5 parts of dried orange peel, 19 parts of gizzard pepsin, 11.5 parts of rhubarb roasted with wine, 18.5 parts of turtle shell, 22 parts of wolfberry bark, 38 parts of radix glehniae, 11.5 parts of roasted licorice, 28 parts of sweet wormwood, 38 parts of ophiopogon root, 9 parts of cassia twig,9 parts of dried ginger, 7 parts of prepared monkshood, 28 parts of snakegourd fruit, 19 parts of coltsfoot flower, 21 parts of aster, 24 parts of mulberry bark, 7 parts of arisaema cum bile, 21 parts of milk vetch and 19 parts of medlar. The active ingredients in the compound oral solution disclosed by the invention disperse in the medium in a molecular or granular state, thus the compound oral solution has the advantages of large dispersion degree and high absorption rate and quickly exerts the treatment effect; and simultaneously, the compound oral solution is easy to realize the divided dose, is convenient to take, reduces the irritation of medicines, has better taste and is especially suitable for old people and children. The compound oral solution disclosed by the invention has the advantages of stable property, high clarity, long shelf life (2 years) and high bioavailability, and has good treatment effect and no toxic side effect when used for treating infantile cough.

The present invention is directed to the use of vascular targeting agents or pharmaceutically acceptable salts thereof for administration in divided doses to a warm-blooded animal, such as a human. Also disclosed is a medicament comprising two or more fraction of doses of a vascular targeting agent, or a pharmaceutically acceptable salt thereof, which together add up to a total daily dose, or administration in divided doses for use in a method of treating a human or warm-blooded animal. A kit comprising two or more fractions of doses of a vascular targeting agent or a pharmaceutically acceptable salt thereof, which together add up to a total daily dose, for administration in divided doses is also disclosed.

A portable self-administrable medication delivery device with “End of Life” feature includes a housing, a drive member within said housing, a locking element and a medicine filled container. The device further provides a “Partial Dose Prevention” feature to deliver an accurate amount of dose with precision. The device is capable of delivering multiple doses of a liquid medicament contained therein without the need of priming the injector prior to administration and allows for repeated administration of a dose of medicament in a simple, easy, safe and accurate manner.

The invention has reference to a procedure and a device for the dosing of a medicine to a consumer. In accordance with the invention, a medicine is supplied in the form of a number of small units, partial doses, containing a determined, equal quantity of the active medical substance, and a number of these units, which correspond to a predetermined dose quantity, total dose, of the active medical substance are taken out and dispensed to the consumer. A device for the carrying out of the procedure in accordance with the invention comprises devices (4, 11, 12) for counting and feeding-out of a number of units, partial doses of the medicine, which correspond to a predetermined dose quantity of the active medical substance and for transport (9) of these units to a dispensing device (9) for dispensing of the above-mentioned dose quantity, total dose, to a consumer.

The invention relates to a medicine treating diabetes-gliclazide tablet which is convenient for distributing dose and a production method. The gliclazide tablet comprises gliclazide, filler, disintegrant and lubricant. The invention adopts the production method that after the gliclazide, the filler and the disintegrant which are of 80 meshes or 100 meshes are mixed, soft materials and particles are made by adding adhesive, dryness and pelletization are carried out by adding the adhesive, uniform mixing is carried out after the lubricant is added, the tablet weight is ensured by testing content, a flat cross stamping tablet is adopted, and the gliclazide tablet can be obtained by packing. On the one hand, the invention solves the problems of accurate tablet and convenient dose distribution, and can conveniently divides the tablet into a one half tablet and a one fourths tablet; on the other hand, the invention solves the problems of the prior same tablet of complex process and high manufacture cost, saves the medicine cost and medicine resources, and finally lowers the therapy cost of a diabetic patient.

The invention discloses a packaging device for storing pellet medicines, which comprises from top to bottom: a pill storage room, an initial dosage area, a second sub-dosage area and a drug delivery area; the pill storage room and the initial dosage area The sub-dose area is separated by a control board to control the pellet medicine in the pill storage chamber to flow into the initial sub-dose area; the primary sub-dose area and the sub-dose area are separated by a partition; the sub-dose area and the sub-dose area The dosing area is separated by a partition. In addition, the invention also discloses the usage method of the device. The invention can take medicine in divided doses at any time according to clinical needs; it can improve patient compliance; it can improve the safety of divided doses and reduce the difficulty of divided doses; The problem of cumbersome dosing operation in the packaging system improves the flexibility of administration.

A method is provided for providing a treatment plan for radiotherapy when delivery is interrupted, the method being performed by a treatment planning system. The method comprises the steps of: detecting that delivery of a first treatment plan has been interrupted; obtaining an indication of delivery of a partial dose representative of a portion of the first treatment plan delivered prior to the interruption; generating a second treatment plan, wherein the partial dose delivery is input to the second treatment plan generation as background dose formation; and optimizing the second treatment plan while taking into account the plurality of scenarios.